{
  "abstract": "Background\n\nThe optimal integration of surgery and definitive chemoradiotherapy (CRT) following modern neoadjuvant immunochemotherapy in stage IIB-IIIA/B non-small-cell lung cancer (NSCLC) remains controversial. Although immune checkpoint inhibitors have substantially improved outcomes in both resectable and unresectable disease, prospective randomized data directly comparing surgery and definitive CRT after neoadjuvant immunochemotherapy are lacking.Methods\n\nInDuRanS is a prospective, multicenter, randomized, open-label phase II trial conducted in Germany. Patients with (borderline) resectable stage IIB-IIIA/B (N2) NSCLC receive three cycles of neoadjuvant immunochemotherapy with durvalumab plus platinum-paclitaxel. Patients with persistent resectability are randomized 1:1 to surgery or definitive CRT. Both treatment arms receive consolidation durvalumab for up to 12 months. The primary endpoint is 2-year event-free survival in 158 randomized patients. Key secondary endpoints include progression-free survival, overall survival, safety and tolerability, health-related quality of life, and an extensive exploratory translational research program.Discussion\n\nInDuRanS is the first randomized trial to directly compare surgery versus definitive CRT within a contemporary multimodal treatment sequence incorporating both neoadjuvant and consolidation immunotherapy in stage IIB-IIIA/B NSCLC. Its results are expected to help define optimal local treatment strategies in an evolving therapeutic landscape. InDuRanS is currently active and open to enrollment as of April 2025, with primary completion anticipated in 2028 (NCT06810609).",
  "abstract_shown": true,
  "affiliations": [
    "Department of Radiation Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany.",
    "Department of Hematology, Oncology & Stem Cell Transplantation, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.",
    "Institute of Experimental Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany.",
    "AstraZeneca GmbH, Hamburg, Germany.",
    "Medical Clinic III of Oncology, Hematology, Rheumatology, and Immune Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany.",
    "Praxis-Netzwerk Onkologie, Troisdorf, Germany.",
    "Department of Radiation Oncology, Klinikum Stuttgart, Stuttgart, Germany.",
    "Department of Radiation Oncology, University of Leipzig, University Hospital Leipzig, Leipzig, Germany.",
    "Department of Radiation Oncology, University of Freiburg, University Medical Center Freiburg, Freiburg, Germany.",
    "Department of Thoracic Surgery, University of Bonn, University Hospital Bonn, Bonn, Germany.",
    "Department of Thoracic Surgery, University of Freiburg, University Medical Center Freiburg, Freiburg, Germany."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Eleni Gkika"
    },
    {
      "affs": [
        1
      ],
      "name": "Cornelius F Waller"
    },
    {
      "affs": [
        0
      ],
      "name": "Cas S Dejonckheere"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Julian P Layer"
    },
    {
      "affs": [
        3
      ],
      "name": "Jan Meiners"
    },
    {
      "affs": [
        4
      ],
      "name": "Peter Brossart"
    },
    {
      "affs": [
        5
      ],
      "name": "Ernst Rodermann"
    },
    {
      "affs": [
        6
      ],
      "name": "Anne Sofie Schiefer"
    },
    {
      "affs": [
        6
      ],
      "name": "Marc Münter"
    },
    {
      "affs": [
        7
      ],
      "name": "Nils H Nicolay"
    },
    {
      "affs": [
        8
      ],
      "name": "Anca L Grosu"
    },
    {
      "affs": [
        8
      ],
      "name": "Andreas Rimner"
    },
    {
      "affs": [
        9
      ],
      "name": "Joachim Schmidt"
    },
    {
      "affs": [
        10
      ],
      "name": "Severin Schmid"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7d0wp5vh1kq0g.bib",
  "cited_by": 1,
  "doi": "10.3389/fonc.2026.1909979",
  "fulltext_url": "https://europepmc.org/articles/PMC13682969",
  "id": "7d0wp5vh1kq0g",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42908627",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Lung Cancer Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7220862175",
  "pdf_url": "https://europepmc.org/articles/PMC13682969?pdf=render",
  "pmcid": "PMC13682969",
  "pmid": "42908627",
  "published": "2026-10-07",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/7d0wp5vh1kq0g.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:53Z",
      "native_id": "MED:42908627",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42908627"
    },
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1909979",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1909979/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.",
  "title_text": "InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:13Z",
  "url": "https://research.draconitic.com/paper/7d0wp5vh1kq0g",
  "venue": "Frontiers in oncology",
  "versions": []
}